INVO Bioscience, Inc.

Equities

INVO

US44984F4019

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
0.98 ^USD	-0.01%		-28.47%	-27.41%

Apr. 18	Top Premarket Decliners	MT
Apr. 17	Sector Update: Health Care Stocks Retreating Late Afternoon	MT

INVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 13, 2023 at 04:01 pm EST

INVO Bioscience, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.974894 million compared to USD 0.235321 million a year ago. Net loss was USD 1.25 million compared to USD 2.55 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 4.19 a year ago. Diluted loss per share from continuing operations was USD 0.7 compared to USD 4.19 a year ago.
For the nine months, revenue was USD 1.64 million compared to USD 0.544054 million a year ago. Net loss was USD 6.04 million compared to USD 8.13 million a year ago. Basic loss per share from continuing operations was USD 5.76 compared to USD 13.42 a year ago. Diluted loss per share from continuing operations was USD 5.76 compared to USD 13.42 a year ago.

Latest news about INVO Bioscience, Inc.

Top Premarket Decliners	Apr. 18	MT
Sector Update: Health Care Stocks Retreating Late Afternoon	Apr. 17	MT
Top Midday Gainers	Apr. 17	MT
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly	Apr. 17	MT
Top Premarket Gainers	Apr. 17	MT
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC	Apr. 07	CI
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	Apr. 04	CI
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	Feb. 08	CI
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	Feb. 08	CI
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	Feb. 08	CI
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.	Dec. 28	CI
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal	Dec. 11	CI
Top Premarket Gainers	Nov. 14	MT
Earnings Flash (INVO) INVO BIOSCIENCE Reports Q3 Revenue $974,894	Nov. 13	MT
INVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	Nov. 10	MT
Transcript : INVO Bioscience, Inc., NAYA Biosciences Inc. - Special Call	23-10-31
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-23	MT
Sector Update: Health Care Stocks Mixed in Monday Afternoon Trading	23-10-23	MT
INVO Bioscience Shares Skyrocket After Signing Deal to Buy NAYA Biosciences	23-10-23	MT
Wall Street Set to Open Lower Monday as National Activity Index Shows Near-Historic Economic Growth	23-10-23	MT
NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. in a reverse merger transaction for $90.7 million.	23-10-22	CI
Transcript : INVO Bioscience, Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Earnings Flash (INVO) INVO BIOSCIENCE Posts Q2 Revenue $315,902, vs. Street Est of $450,000	23-08-14	MT

Chart INVO Bioscience, Inc.

Duration

Period

More charts

Company Profile

INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Companyâs flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the womanâs body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for INVO Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.98

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
INVO BIOSCIENCE, INC.	-27.41%	2.69M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution